Peptide encyclopedia

52 peptides across 10 categories — each with mechanism, evidence level, regulatory status, and the protocols reported in the research literature.

See the research landscape — evidence levels, goals & routes at a glance →

Suggested for you

These are popular starting points. Create an account to personalize them to your goals.

Goal

Recovery & Healing

7

Growth Hormone Secretagogues

10

CJC-1295 + Ipamorelin

CJC/Ipa stack

A commonly studied stack pairing a GHRH analogue (CJC-1295) with a selective GH secretagogue (Ipamorelin) to raise growth-hormone pulses.

Moderate evidenceResearch peptide — not FDA-approved

CJC-1295 with DAC

CJC-1295 DAC

A long-acting GHRH analogue with a Drug Affinity Complex that extends its half-life to several days.

Emerging evidenceResearch peptide — not FDA-approved

GHRP-2

Pralmorelin

A growth-hormone-releasing peptide studied for strong GH stimulation, also used clinically as a diagnostic agent in some regions.

Moderate evidenceResearch peptide — not FDA-approved

GHRP-6

Growth Hormone Releasing Peptide 6

An early growth-hormone-releasing peptide noted for pronounced appetite stimulation alongside GH release.

Moderate evidenceResearch peptide — not FDA-approved

Hexarelin

Examorelin

A potent GH-releasing peptide studied for strong GH stimulation and possible cardiac effects.

Emerging evidenceResearch peptide — not FDA-approved

HGH Fragment 176-191

AOD fragment

A fragment of growth hormone studied specifically for fat metabolism without the broader GH effects.

Emerging evidenceResearch peptide — not FDA-approved

Ipamorelin

NNC 26-0161

A selective GH secretagogue peptide known for a clean profile with minimal effect on cortisol or prolactin.

Moderate evidenceResearch peptide — not FDA-approved

MK-677 (Ibutamoren)

Ibutamoren

An orally active, non-peptide ghrelin-receptor agonist studied for sustained increases in GH and IGF-1.

Moderate evidenceResearch peptide — not FDA-approved

Sermorelin

GHRH 1-29

A GHRH analogue historically used clinically to assess and stimulate natural growth-hormone production.

Moderate evidencePrescription only

Tesamorelin

Egrifta

An FDA-approved GHRH analogue indicated to reduce excess visceral abdominal fat in HIV-associated lipodystrophy.

Established evidenceFDA-approved

Metabolic & Weight

8

Longevity & Cellular

7

Cognitive & Mood

6

Immune

4

Sexual Health

1

Skin & Hair

5

Hormonal Axis

3

Sleep / Circadian

1